✓ No fee unless you win✓ Free & confidential review✓ Board-certified trial attorney

Depo-Provera study puts four-year exposure details in focus for meningioma reviews

Last reviewed: September 29, 2026

A new U.S. study does not make every old Depo-Provera
shot look the same. For women trying to make sense of a
meningioma diagnosis, that is the useful part.

The study, published in JAMA Neurology, looked at a
large U.S. health-record database. It reported a higher
relative risk of meningioma diagnosis among women who
used depot medroxyprogesterone acetate, the injectable
medication sold as Depo-Provera and in generic forms.
The signal was clearest for people who used the shot
for more than four years, or who started after age 31.

That is not a magic cutoff. It is not a promise about
any one claim. But it is the kind of detail that can
change a first review from, "I think I used it for a
while," into a dated timeline that can actually be
checked.

The federal Depo-Provera cases are grouped in MDL 3140.
Plaintiffs allege that long-term use of injectable
medroxyprogesterone acetate can cause intracranial
meningioma and that U.S. warnings came too late. Pfizer
denies the allegations and says the medication is safe
and effective when used as directed.

Our main Depo-Provera lawsuit
page
covers the MDL background. This page is about one
narrower question: what the newer U.S. study may mean
when a potential claim is being screened.

What the U.S. study found

The JAMA Neurology researchers used the TriNetX U.S.
database and compared women exposed to depot
medroxyprogesterone acetate with matched control
groups. The paper reported a relative risk of 2.43 for
meningioma diagnosis compared with controls. The
authors also reported that the risk was concentrated in
patients with longer than four years of exposure or who
began the prescription after age 31.

Those are population numbers. They do not prove what
caused one person's tumor. They also do not mean that
most Depo-Provera users will develop a meningioma. The
same study reported a number needed to harm of 1,152
for depot medroxyprogesterone acetate, meaning the
absolute risk remained low even though the relative
risk was higher.

For claim review, the takeaway is plain: dates matter.
A person with three remembered shots and no clinic
records is in a different posture from someone who can
document years of injections before a later meningioma
diagnosis.

Why duration and starting age may matter

Depo-Provera is usually given every three months. Years
later, that makes the paper trail awkward. The shot may
have been given at an OB/GYN office, a county health
department, a primary-care clinic, a school clinic, or
a family-planning clinic. Sometimes the proof is not in
a retail pharmacy file at all. It may be buried in an
office chart or an insurance billing record.

The new study puts extra weight on two simple
questions:

How many months or years of DMPA injections can be documented?
How old was the patient when the injections started and stopped?

A serious review will still look at more than exposure
length. It may also need the meningioma diagnosis date,
tumor location, treatment history, pathology if surgery
occurred, and records showing symptoms or follow-up
care. The study just gives one more reason not to rely
on memory alone.

If you are gathering records, ask for dated injection
records, not just a note that says "birth control
shot." Ask imaging centers for MRI or CT reports. If
there was surgery, ask for operative and pathology
reports. If you used more than one clinic, send a
separate request to each one.

How this fits with the BMJ study and the FDA label

The U.S. study is not the first warning sign in the
record. A 2024 BMJ national case-control study from
France reported an increased risk of intracranial
meningioma requiring surgery with prolonged use of
injectable medroxyprogesterone acetate. That study is
one reason these claims drew national attention.

The current U.S. prescribing information for
Depo-Provera CI now includes a meningioma warning. The
label says cases have been reported after repeated
administration of medroxyprogesterone acetate,
primarily with long-term use. It also says clinicians
should monitor patients for signs and symptoms of
meningioma and discontinue Depo-Provera CI if a
meningioma is diagnosed.

That warning matters. It is still not medical advice
from us. Do not stop or change contraception because of
a lawsuit article. If you have a meningioma diagnosis,
a past meningioma, or questions about Depo-Provera,
talk with the clinician who knows your medical history.

Where MDL 3140 stands

The federal Depo-Provera litigation is centralized in
the Northern District of Florida before Judge M. Casey
Rodgers. The court's MDL page says the transferred
cases share allegations that injectable Depo-Provera or
generic versions can cause users to develop one or more
meningiomas. The same court page notes that defendants
maintain the medication is safe and effective.

Public materials have discussed settlement activity and
continued causation proceedings. That does not give
anyone a public settlement grid. It also does not mean
every person with a meningioma is automatically in or
out. A careful review still starts with the person's
records.

We also track other prescription-drug claims where
medical proof matters, including Ozempic and GLP-1
injury
claims
and Suboxone dental injury
claims.
Depo-Provera reviews are different because the exposure
proof may be spread across injection records, clinic
charts, insurance files, and imaging reports.

Plain-English FAQ

Does the JAMA Neurology study prove my meningioma was caused by Depo-Provera?

No. It reports a population-level association and risk
pattern. An individual legal review still depends on
exposure records, diagnosis records, timing, medical
history, and the law that applies to the claim.

Is four years of use a filing requirement?

Not by itself. The study found the clearest risk signal
with longer than four years of exposure, but actual
claim criteria can depend on the litigation, medical
facts, and state deadlines.

What should I collect first if I used Depo-Provera and later had a meningioma?

Start with dated injection records and records proving
the meningioma diagnosis. That usually means MRI or CT
reports, neurosurgery notes, operative reports,
pathology reports, and radiation records if radiation
was used.

Attorney advertising and medical disclaimer

This article is for general information only. It is not
medical advice or legal advice. Reading it or
submitting a form does not create an attorney-client
relationship. Prior results do not guarantee a similar
outcome. Every claim depends on the person's records,
exposure history, deadlines, and applicable law.

Sources

Robert B. Baker, Board-Certified Civil Trial Attorney

Claims reviewed by Baker Legal Team
Robert B. Baker, Esq., B.C.S. — Board-Certified Civil Trial Lawyer. 30+ years of trial experience, more than $400 million recovered for clients. About Robert Baker →